Skip to main content
SpringerLink
Log in

Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder

  • Original Paper
  • Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

We evaluated the toxicity of high-dose local interleukin-2 (IL-2) in 18 patients not eligible for standard treatment of advanced transitional cell bladder carcinoma. Seven received continuous high-dose local natural IL-2 via pump system in the bladder for up to 420 days. 11 received cyclic high-dose local natural IL-2 or recombinant IL-2 for up to 420 days. Treatment was well tolerated and, considering the low rate of toxicity, could be offered in an outpatient setting. Except for local contrast-media hypersensitivity, no serious side-effects were observed. This study provides a basis for the non-toxic use of local IL-2 in future studies to evaluate effectiveness of the treatment or prophylaxis of patients with superficial bladder cancer in order to prevent recurrences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IL-2 :

interleukin-2

TUR :

transurethral resection

TNFα:

tumor necrosis factor α

References

  • Bradley LM, Duncan DD, Tonkonogy S, Swain SL (1991) Characterization of antigen-specific CD4+ effector T cells in vivo: immunization results in a transient population of MEL-14−, CD45 RB− helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma. J Exp Med 174:547–559

    Google Scholar 

  • Heinzer H, Huland H, Huland E (1990) Activated eosinophil leucocytes in interleukin-2 treated patients: evidence for a new antitumor effector mechanism (abstract). J Cancer Res Clin Oncol 369

  • Herr H (1987) Conservative management of muscle-infiltrating bladder cancer: prospective Experience. J Urol 138:1162–1163

    Google Scholar 

  • Huland E, Huland H (1989) Local continuous high dose interleukin-2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469–5474

    Google Scholar 

  • Huland E, Huland H (1992) Tumor associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 118:463–467

    Google Scholar 

  • Huland E, Heinzer H, Huland H (1991) Increase toxicity to local and systemic n-Interleukin-2 (nIL-2) after iodine-containing radiographic contrast media (ICCM). J Urol 145:334

    Google Scholar 

  • Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 147:3443–3448

    Google Scholar 

  • Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7:7–20

    Google Scholar 

  • Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986a) High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment related morbidity, and histological findings. JAMA 256:3117–3124

    Google Scholar 

  • Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA (1986b) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 12:2764–2772

    Google Scholar 

  • Mertelsmann R, Welte K (1986) Human interleukin-2: molecular biology, physiology and clinical possibilities. Immunobiology 172:400–419

    Google Scholar 

  • Sosnowski JT, De Haven JI, Abraham FM, Riggs DR, Lamm DL (1992) Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guérin and interleukin-2 immunotherapy. J Urol 147:1439–1443

    Google Scholar 

  • Wang MH, Flad HD, Böhle A, Chen YQ, Ulmer AJ (1991) Cellular cytoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol Lett 27:191–197

    Google Scholar 

  • West WH, Tauer KW, Yannelli, JR, Marshall GD, Orr DW, Thurmann GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Hamburg, Martinistrasse 52, D-20246, Hamburg, Germany

    Hartwig Schwaibold, Edith Huland, Hans Heinzer & Hartwig Huland

  2. Fa. Biotest, Dreieich, Germany

    Udo Schwuléra

Authors
  1. Hartwig Schwaibold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edith Huland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans Heinzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Udo Schwuléra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hartwig Huland
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This study was supported by the Deutsche Forschungsgemeinschaft

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwaibold, H., Huland, E., Heinzer, H. et al. Toxicity of local, continuous and cyclic, high-dose bladder perfusion with recombinant and natural interleukin-2 in advanced cancer of the urinary bladder. J Cancer Res Clin Oncol 121, 239–246 (1995). https://doi.org/10.1007/BF01366969

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01366969

Key words

Search

Navigation